[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,450
Citations 0
JAMA Clinical Evidence Synopsis
April 7, 2015

Association Between Perioperative Low-Molecular-Weight Heparin vs Unfractionated Heparin and Clinical Outcomes in Patients With Cancer Undergoing Surgery

Author Affiliations
  • 1Clinical Research Institute, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
  • 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
  • 3Department of Medicine, McMaster University, Hamilton, Ontario, Canada
JAMA. 2015;313(13):1364-1365. doi:10.1001/jama.2015.498
Abstract

Clinical Question  In patients with cancer undergoing surgery, what is the association between perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes?

Bottom Line  When used for perioperative thromboprophylaxis, there are no differences in the association of LMWH vs unfractionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocytopenia in patients with cancer.

×